Name | Value |
---|---|
Revenues | 296.2K |
Cost of Revenue | 248.4K |
Gross Profit | 47.7K |
Operating Expense | 2,712.0K |
Operating I/L | -2,664.2K |
Other Income/Expense | -30.6K |
Interest Income | 156.2K |
Pretax | -2,783.9K |
Income Tax Expense | 2,985.8K |
Net Income/Loss | -5,769.8K |
Avalon GloboCare Corp. operates commercial real estate properties in the US and China, offering medical consulting services, research studies, and management services in immunotherapy and second opinion/referral services. Its leading candidates include AVA-001, an anti-CD19 CAR-T, and AVA-011, a pre-clinical stage RNA-based FASH-CARTM cell therapy platform. The company also develops avalon clinical-grade tissue-specific exosome (ACTEX) and therapeutic and diagnostic targets utilizing QTY-code protein design technology with MIT. Additionally, it has a strategic partnership with the University of Natural Resources and Life Sciences in Vienna to develop an S-layer vaccine against SARS-CoV-2. Avalon GloboCare Corp. also promotes standardization related to the exosome industry.